|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 23, No 24 (August 20), 2005: pp. 5493-5500 © 2005 American Society of Clinical Oncology. DOI: 10.1200/JCO.2005.10.190 Profile of Daily Life in Children With Brain Tumors: An Assessment of Health-Related Quality of LifeFrom the Departments of Neurology, Pediatrics, Neurosurgery, and Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA; Department of Anesthesiology, University of Washington Medical Center, Seattle, WA; and Texas A&M University, College Station, TX Address reprint requests to Paul G. Fisher, MD, Stanford University Cancer Center, Room CC2220, 875 Blake Wilbur Dr, Stanford, CA 94305-5826; e-mail: pfisher{at}stanford.edu PURPOSE: The survival of children with CNS tumors approaches 70%, yet health-related quality of life (HRQOL) has not been investigated rigorously in this population. We aimed to show that universal assessment of HRQOL could be obtained easily by using the PedsQL 4.0 and to provide a composite profile of their daily lives. PATIENTS AND METHODS: The PedsQL was administered to all patients seen in the neuro-oncology clinic at Lucile Packard Children's Hospital (Palo Alto, CA) from December 2001, to September 2002. Patients were compared with healthy controls by using two-sided t tests to evaluate statistically significant differences. RESULTS: One hundred thirty-four patients (73 male; mean age ± standard deviation, 11.8 ± 5.4 years; 55 had low-grade glioma, 32 had medulloblastoma/primitive neuroectodermal tumor/embryonal tumor, 17 had malignant astrocytoma, nine had germ-cell tumor, and 21 had other types of tumors) were assessed, each in less than 20 minutes. Scores on both child and parent-proxy reports for the total HRQOL, psychosocial, physical, emotional, social, and school-functioning scales were all significantly lower than controls (P < .01). Patients with low-grade glioma were reported to have the highest total HRQOL. Children receiving radiation therapy (XRT) but no chemotherapy had significantly lower total, psychosocial, emotional, and social functioning than those receiving other treatments, including XRT plus chemotherapy. CONCLUSION: The PedsQL can be used to assess HRQOL rapidly and easily in children with CNS tumors, who have significantly worse HRQOL than healthy children. Children receiving XRT fare worse overall; chemotherapy added to XRT does not seem to worsen HRQOL. Assessment of HRQOL should be included as an outcome in future clinical trials. Supported by the National Brain Tumor Foundation Pediatric Research Grant. Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31, 2003. Authors' disclosures of potential conflicts of interest are found at the end of this article.
Related Editorial
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|